
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 14, 2023, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR CARBOPROST TROMETHAMINE INJECTION USP".
Filed with NSE ·

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 14, 2023, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR CARBOPROST TROMETHAMINE INJECTION USP".
6ix hasn’t read this filing yet.
Caplin Point Laboratories Limited on 6ix
Follow Caplin Point Laboratories into a list and get an email when it puts out news.
Follow Caplin Point Laboratories